Research programme: antibacterials - Gilead Sciences
Alternative Names: Antibacterials research programme - Gilead SciencesLatest Information Update: 18 Jul 2002
At a glance
- Originator Gilead Sciences
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 19 Jun 2000 Preclinical development for Bacterial infections in USA (Unknown route)